Sector News

UCB acquires gene therapy specialist Handl Therapeutics

November 13, 2020
Life sciences

Company also announces new collaboration with Lacerta Therapeutics.

UCB has announced its acquisition of Belgium-based gene therapy company Handl Therapeutics, in a move that will bolster its pipeline programmes, capabilities and platforms in the gene therapy space.

UCB also announced a new collaboration with Lacerta Therapeutics, a clinical stage gene therapy company based in Florida, US.

Handl Therapeutics is focused on creating disease modifying in vivo gene therapies to treat neurodegenerative disease through proprietary adeno-associated virus (AAV) capsid technology.

According to UCB, Handl has a strong international network which enables access to global capabilities and expertise – the company combines technology platforms and scientific advances licenced from KU Leuven (Belgium), Centre for Applied Medical Research (CIMA Universidad de Navarra, Spain), University of Chile (Chile) and King’s College London (UK).

Following the acquisition by UCB, the Handl Therapeutics team will continue to be based in Leuven, Belgium while working closely with UCB’s international research teams.

In addition to its acquisition of Handl Therapeutics, UCB has also signed a research collaboration and licensing agreement with Lacerta Therapeutics.

The focus of this agreement is to make AAV-based therapies for central nervous system (CNS) diseases with high unmet need.

Lacerta is set to lead the research, preclinical activities and early manufacturing process development, while UCB will lead IND-enabling studies, manufacturing and clinical development.

“The acquisition of Handl Therapeutics and the new partnership with Lacerta Therapeutics offers us the potential to drive a fundamental change in how diseases are treated, by moving us from treating symptoms to disease modification and eventually towards a cure,” said Dhavalkumar Patel, chief scientific officer of UCB.

“We are delighted to be able to welcome a rich diversity of talent and expertise from both Handl Therapeutics and Lacerta Therapeutics. With their deep and wide-ranging knowledge, novel gene therapy platforms and drive for innovation, I am confident that together we will transform the lives of people living with severe neurodegenerative diseases,” he added.

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend